Intervention Protocol

Alpha2 adrenergic agonists for attention deficit hyperactivity disorder (ADHD)

  1. Michael Venables1,*,
  2. Evangelia Ntzani2,
  3. Yingfen Hsia3,
  4. Donna Gillies4

Editorial Group: Cochrane Developmental, Psychosocial and Learning Problems Group

Published Online: 15 AUG 2012

DOI: 10.1002/14651858.CD010016


How to Cite

Venables M, Ntzani E, Hsia Y, Gillies D. Alpha2 adrenergic agonists for attention deficit hyperactivity disorder (ADHD) (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 8. Art. No.: CD010016. DOI: 10.1002/14651858.CD010016.

Author Information

  1. 1

    Child and Adolescent Mental Health Services, Horsham, Sussex, UK

  2. 2

    University of Ioannina School of Medicine, Department of Hygiene and Epidemiology, Ioannina, Greece

  3. 3

    School of Pharmacy, University College London, Department of Practice and Policy, London, UK

  4. 4

    Western Sydney and Nepean Blue Mountains Local Health Districts - Mental Health, Parramatta, NSW, Australia

*Michael Venables, Child and Adolescent Mental Health Services, New Park House, North Street, Horsham, Sussex, RH12 1RJ, UK. Michael.Venables@sussexpartnership.nhs.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 15 AUG 2012

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

In people of all ages, to assess the efficacy and safety of alpha2 agonists, alone or as an adjunct therapy, in treating core symptoms of ADHD or hyperkinetic disorder, associated comorbid symptoms and side effects.